Johnson & Johnson buys Heartport for $81 million
This article was originally published in Clinica
Executive Summary
Heartport, the less invasive cardiac surgery company, which has never delivered on its early promise in face of the shift to beating heart surgery, has been acquired by Johnson & Johnson for J&J shares totalling $81 million - or $2.72 a share. Heartport will become a wholly owned subsidiary operating as part of the Ethicon Worldwide surgical instruments division of J&J.